Co-Diagnostics, Inc.

NasdaqCM:CODX Stock Report

Market Cap: US$33.8m

Co-Diagnostics Past Earnings Performance

Past criteria checks 0/6

Co-Diagnostics's earnings have been declining at an average annual rate of -44.7%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been declining at an average rate of 14.8% per year.

Key information

-44.7%

Earnings growth rate

-42.2%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate-14.8%
Return on equity-64.7%
Net Margin-563.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation

Jun 14
Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation

One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%

May 18
One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%

A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Apr 14
A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Co-Diagnostics: Hold Thesis Remains Well Intact

Sep 07

Co-Diagnostics stock sinks ~37% after hours on Q2 results miss, hurt by lower volumes

Aug 11

Co-Diagnostics spikes on shipments of monkeypox test

Jul 11

Estimating The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Jul 06
Estimating The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Co-Diagnostics: Well Priced, Long-Term Value Remains Too Distant

Jun 21

Co-Diagnostics: Where's Eikon?

Apr 03

Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate

Mar 28
Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate

Co-Diagnostics: Swinging For The Fences

Jan 24

Does Co-Diagnostics (NASDAQ:CODX) Deserve A Spot On Your Watchlist?

Dec 28
Does Co-Diagnostics (NASDAQ:CODX) Deserve A Spot On Your Watchlist?

Why Co-Diagnostics Is A Solid Covid-19 Play

Aug 19

Co-Diagnostics, Inc.'s (NASDAQ:CODX) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Aug 14
Co-Diagnostics, Inc.'s (NASDAQ:CODX) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Revenue & Expenses Breakdown

How Co-Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:CODX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 247-412022
30 Jun 249-382023
31 Mar 247-392124
31 Dec 237-352123
30 Sep 235-432222
30 Jun 237-382221
31 Mar 2312-322119
31 Dec 2234-142217
30 Sep 2253152015
30 Jun 2278282216
31 Mar 22101402617
31 Dec 2198372515
30 Sep 21105422514
30 Jun 219646219
31 Mar 219351155
31 Dec 207542133
30 Sep 20482892
30 Jun 20261072
31 Mar 202-651
31 Dec 190-651
30 Sep 190-651
30 Jun 190-651
31 Mar 190-651
31 Dec 180-651
30 Sep 180-651
30 Jun 180-851
31 Mar 180-841
31 Dec 170-741
30 Sep 170-631
30 Jun 170-311
31 Mar 170-211
31 Dec 160-211
30 Sep 160-211
31 Dec 150-211

Quality Earnings: CODX is currently unprofitable.

Growing Profit Margin: CODX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CODX is unprofitable, and losses have increased over the past 5 years at a rate of 44.7% per year.

Accelerating Growth: Unable to compare CODX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CODX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.4%).


Return on Equity

High ROE: CODX has a negative Return on Equity (-64.73%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies